<div id="readability-page-1"><p>Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Biogen, boosting the price target to $250.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Salveen Richter has given his Buy rating due to a combination of factors, primarily centered on the strong momentum of Leqembi’s launch and its outperformance versus prior expectations. The recent quarter showed Leqembi revenue ahead of both Goldman Sachs estimates and consensus, with notable strength across the U.S., Japan, and China, supporting confidence in a faster build-out of the Alzheimer’s franchise.</p> <p>Richter’s view also reflects Eisai’s newly issued Leqembi revenue outlook, which aligns with or exceeds market forecasts and is underpinned by anticipated catalysts such as broader use of blood-based biomarkers, the potential approval and uptake of the IQLIK subcutaneous formulation, and future indications that could move treatment earlier in the disease course. These dynamics, combined with positive ex-U.S. opportunities and an upward revision of the BIIB price target from $238 to $250, underpin the constructive stance on Biogen shares.</p> </div>

BIIB

<p>Goldman Sachs analyst Salveen Richter has reiterated a Buy rating on Biogen, raising the price target from $238 to $250. This decision is driven by the strong performance of Leqembi, which exceeded revenue expectations in the recent quarter. Factors supporting this outlook include a favorable revenue forecast from Eisai, anticipated catalysts for broader use of biomarkers, and potential new formulations that could enhance treatment options.</p>

- Goldman Sachs analyst Salveen Richter maintains a buy rating on Biogen and raises the target price to $250.00, reflecting confidence in Leqembi's strong performance.  
- Leqembi's recent earnings exceeded expectations and showed robust sales in the U.S., Japan, and China, reinforcing optimism in Alzheimer's treatment growth.  
- Factors supporting this positive outlook include Eisai's revenue forecast for Leqembi, potential approval of new treatments, and enhanced opportunities outside the U.S.

Tip Ranks

Biogen

Proshares Ultra Nasdaq Biotech

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VG Health

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

iShares Global Healthcare

Goldman Sachs

Eisai Co., Ltd.

GS Hldg R

Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250